A detailed history of Caption Management, LLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Caption Management, LLC holds 90,000 shares of AUPH stock, worth $812,700. This represents 0.01% of its overall portfolio holdings.

Number of Shares
90,000
Previous 60,000 50.0%
Holding current value
$812,700
Previous $342,000 92.69%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.81 - $5.78 $29,225 - $35,119
6,076 New
6,076 $34,000
Q4 2023

Feb 14, 2024

BUY
$7.13 - $9.49 $577,530 - $768,690
81,000 Added 243.98%
114,200 $1.03 Million
Q3 2023

Nov 14, 2023

BUY
$7.77 - $12.27 $257,964 - $407,364
33,200 New
33,200 $257,000
Q4 2022

Feb 14, 2023

SELL
$4.11 - $8.14 $148,371 - $293,854
-36,100 Reduced 62.24%
21,900 $94,000
Q3 2022

Nov 14, 2022

BUY
$6.66 - $12.39 $290,895 - $541,170
43,678 Added 304.97%
58,000 $436,000
Q2 2022

Aug 15, 2022

SELL
$8.95 - $12.8 $286,104 - $409,177
-31,967 Reduced 69.06%
14,322 $144,000
Q1 2022

May 13, 2022

SELL
$10.05 - $22.48 $273,018 - $610,691
-27,166 Reduced 36.98%
46,289 $574,000
Q4 2021

Feb 11, 2022

BUY
$17.78 - $33.08 $959,319 - $1.78 Million
53,955 Added 276.69%
73,455 $1.68 Million
Q1 2021

May 17, 2021

SELL
$12.3 - $18.73 $1.17 Million - $1.79 Million
-95,500 Reduced 83.04%
19,500 $253,000
Q3 2020

Nov 16, 2020

SELL
$13.19 - $16.66 $430,745 - $544,065
-32,657 Reduced 22.12%
115,000 $1.69 Million
Q2 2020

Aug 14, 2020

BUY
$14.12 - $18.33 $1.6 Million - $2.08 Million
113,457 Added 331.75%
147,657 $2.4 Million
Q1 2020

May 15, 2020

BUY
$11.34 - $21.46 $104,328 - $197,432
9,200 Added 36.8%
34,200 $497,000
Q4 2019

Feb 13, 2020

BUY
$3.88 - $21.42 $97,000 - $535,500
25,000 New
25,000 $506,000

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.28B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.